PURE Bioscience Statistics
Total Valuation
PURE Bioscience has a market cap or net worth of 17.12 million. The enterprise value is 19.72 million.
| Market Cap | 17.12M |
| Enterprise Value | 19.72M |
Important Dates
The last earnings date was Monday, October 28, 2024.
| Earnings Date | Oct 28, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
PURE Bioscience has 111.86 million shares outstanding. The number of shares has increased by 0.41% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 111.86M |
| Shares Change (YoY) | +0.41% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 41.26% |
| Owned by Institutions (%) | n/a |
| Float | 65.71M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 8.72 |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -5.89 |
| EV / Sales | 10.04 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.10
| Current Ratio | 1.10 |
| Quick Ratio | 0.88 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -20.20 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -148.08% |
| Return on Capital (ROIC) | -284.02% |
| Revenue Per Employee | 163,583 |
| Profits Per Employee | -279,167 |
| Employee Count | 12 |
| Asset Turnover | 1.49 |
| Inventory Turnover | 11.26 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +49.53% in the last 52 weeks. The beta is 0.06, so PURE Bioscience's price volatility has been lower than the market average.
| Beta (5Y) | 0.06 |
| 52-Week Price Change | +49.53% |
| 50-Day Moving Average | 0.09 |
| 200-Day Moving Average | 0.08 |
| Relative Strength Index (RSI) | 69.71 |
| Average Volume (20 Days) | 34,585 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 1.70 |
Income Statement
In the last 12 months, PURE Bioscience had revenue of 1.96 million and -3.35 million in losses. Loss per share was -0.03.
| Revenue | 1.96M |
| Gross Profit | 1.15M |
| Operating Income | -3.13M |
| Pretax Income | -3.35M |
| Net Income | -3.35M |
| EBITDA | -2.98M |
| EBIT | -3.13M |
| Loss Per Share | -0.03 |
Balance Sheet
The company has 349,000 in cash and 2.95 million in debt, giving a net cash position of -2.60 million or -0.02 per share.
| Cash & Cash Equivalents | 349,000 |
| Total Debt | 2.95M |
| Net Cash | -2.60M |
| Net Cash Per Share | -0.02 |
| Equity (Book Value) | -2.86M |
| Book Value Per Share | -0.03 |
| Working Capital | 72,000 |
Cash Flow
| Operating Cash Flow | -2.53M |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
Gross margin is 58.69%, with operating and profit margins of -159.50% and -170.66%.
| Gross Margin | 58.69% |
| Operating Margin | -159.50% |
| Pretax Margin | -170.66% |
| Profit Margin | -170.66% |
| EBITDA Margin | -151.96% |
| EBIT Margin | -159.50% |
| FCF Margin | n/a |
Dividends & Yields
PURE Bioscience does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -0.41% |
| Shareholder Yield | -0.41% |
| Earnings Yield | -19.57% |
| FCF Yield | n/a |
Stock Splits
The last stock split was on August 15, 2012. It was a reverse split with a ratio of 0.125.
| Last Split Date | Aug 15, 2012 |
| Split Type | Reverse |
| Split Ratio | 0.125 |
Scores
PURE Bioscience has an Altman Z-Score of -242.09. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -242.09 |
| Piotroski F-Score | n/a |